Choosing an ED Device
The device treatment ladder - least to most invasive
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Reflects AUA/EAU/ISSM guideline treatment sequencing
Reference only. Not medical advice.
What can go wrong
The central honest point is that invasiveness and irreversibility rise as you climb the ladder. Vacuum devices and rings are cheap and low-risk but give a mechanical, sometimes cool/hinged erection; injections are highly effective but carry priapism and fibrosis risk and high discontinuation; a penile implant is the most reliable but is surgery with infection risk and permanent loss of natural erectile function. No single option is best for everyone, matching depends on ED severity, comorbidities, dexterity, partner factors, and patient preference.
This is something to take to a clinician. The Atlas can tell you what is known about choosing an ed device in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
This monograph frames how ED devices and non-oral therapies fit together as a treatment ladder that guidelines (AUA, EAU, ISSM) sequence from least to most invasive. The general order runs: address reversible causes and try oral PDE5 inhibitors first; then low-risk external devices (vacuum devices, constriction rings, topical Eroxon); then intracavernosal injection therapy; and finally, only after less invasive options fail or are declined, a surgically implanted penile prosthesis, an effective but irreversible last resort.
Start least invasive; the implant is the floor, not the goal.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
The ladder logic is risk-proportionality: begin with interventions that are reversible and low-risk (pills, VEDs, rings, topical gel), escalate to injections when those fail, and reserve prosthesis surgery, which destroys native erectile tissue and cannot be undone, for men who have failed or cannot use everything upstream. Devices beat pills when ED is severe, when the cause is not drug-responsive (e.g. significant nerve injury after prostatectomy, marked vascular disease), or when a man cannot take PDE5 inhibitors (nitrate use, intolerance).
What people get wrong
Often saidA penile implant is the goal of ED treatment
ActuallyThe implant is the floor, the reliable last resort when everything less invasive fails or is declined, not the aim. Guidelines push clinicians to exhaust reversible causes and less invasive options first because implant surgery is irreversible.
Often saidDevices are only for men who can't take pills
ActuallyDevices are also chosen when pills work poorly (severe or post-prostatectomy ED), when a man wants to avoid systemic drugs, or when reliability matters more than convenience.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
Against oral PDE5 inhibitors, devices win on reliability in severe or non-drug-responsive ED (VED and injections work regardless of the underlying pill-responsiveness) and on avoiding systemic drug effects, but lose on convenience and naturalness. Among devices, cost and reversibility fall as efficacy and invasiveness rise, from a cheap reusable vacuum pump up to a several-thousand-dollar irreversible implant.
| Device / Therapy | How it works | Efficacy | Invasiveness |
|---|---|---|---|
| Vacuum erection device | Vacuum draws blood in; ring traps it | ~71-85%, lower long-term use | Low (external, reusable) |
| Constriction ring | Slows venous outflow to sustain erection | Adjunct / mild ED | Very low (external) |
| Eroxon (MED3000) gel | Topical cooling/warming, physical action | Modest; milder ED | Very low (topical, OTC) |
| Intracavernosal injection | Vasoactive drug injected into corpora | ~70-90% | Moderate (self-injection) |
| Intraurethral alprostadil (MUSE) | Urethral pellet of alprostadil | ~30-40% (discontinued US) | Low-moderate (urethral) |
| External support device | Rigid external brace, no erection needed | Niche; limited data | Low (worn externally) |
| Malleable penile implant | Bendable rods, permanent semi-rigidity | High; ~75-77% satisfaction | High (surgery, irreversible) |
| Inflatable penile prosthesis | Hydraulic cylinders, pump, reservoir | High; ~90%+ satisfaction, ~87-91% multi-yr survival | Highest (surgery, irreversible) |
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Costs span from ~$20-$60 rings and ~$100-$500 vacuum devices, through per-dose injection costs (cheap compounded Trimix to pricey branded alprostadil), up to $9,000-$15,000+ all-in for an implant, though a one-time implant can beat years of recurring injection or intraurethral costs and is often insurance-covered when prior therapies fail.
At a glance
- Guideline bodies
- AUA, EAU, ISSM
- First line
- PDE5 inhibitors / reversible causes
- Last resort
- Inflatable penile prosthesis
- Key principle
- Least invasive that works, first
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Choosing an ED Device. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
AUA erectile dysfunction guidelinereported
Strong recommendation for IPP in appropriately selected men who fail, cannot tolerate, or decline less invasive therapy
Medicare ED out-of-pocket cost modelreported
Ongoing therapies (annual intraurethral ~$4,022, injections ~$3,947) can exceed the amortized cost of a one-time implant